GPR12-Targeted Drug Discovery Services

Introduction

G protein-coupled receptor 12 (GPR12) is a protein coding gene. It is encoded by the GPR12 gene. It is a G protein-coupled orphan receptor genetically related to type 1 and type 2 cannabinoid receptors (CB1 and CB2). CB1 and CB2 are ancient proteins expressed all over the body. Among its related pathways are peptide ligand-binding receptors. Gene ontology (GO) annotations related to this gene include G protein-coupled receptor activity and phosphatidylcholine binding.[provided by GeneCards] In human CNS, GPR12 is mainly expressed in the basal ganglia, the cerebellum, and the cerebral cortex, in a lesser extent in the thalamus, the hippocampus, the olfactory region, and the amygdalae, and scarcely expressed in the hypothalamus, the midbrain, and the corpus callosum. In other words, GPR12 has been mainly detected in structures closely related to cognitive processes, including learning, memory, and the brain reward system, such as the cerebral cortex, the hippocampus, and the striatum. GPR12 has the property of exhibiting a basal G protein-coupling activity, since it upregulates the adenylate cyclase signaling cascade without any activating ligand.

Direction of Drugs Discovery

• Developing New Clinical Effects on GPR12 from Existing Drugs

Drugs

To be updated

What We Offer

Target Testing

CD BioSciences provides GPR12 testing services by WB or IHC assay. The results of GPR12 testing are used to evaluate the activities of candidates against GPR12 or targeted diseases. You can choose one or more testing ways to detect the level of GPR12 according to your experiment.

Hit Identification (show more)

The goal of early drug discovery is to find novel lead compounds that have the desired potency, selectivity, and ADMET properties for pre-clinical evaluation.
CD BioSciences offers hit identification services to make your finding of targeted compounds more successful and faster.
• High-Throughput Screening
• GPR12-Targeted in Silico Virtual Screening
• Fragment-Based Screening
• High-Content Screening

Antibody Drugs Development Services (show more)

Antibody drugs exhibit many incomparable advantages, such as high specificity, affinity, and efficiency, which is an emerging direction on targeted drug development. CD BioSciences provides comprehensive services on GPR12-targeted antibody drugs development with professional technology, extensive experience, and advanced equipment.
• Antibody Preparation Services
• Phage Display Services
• Antibody-Drug Conjugates
• Bispecific Antibody Services
• Antibody Humanization Services

Pharmacological Experiments (show more)

We will create a specific experimental plan according to your requirements, including but not limited to
• Pharmacokinetics / Pharmacodynamics
• Pharmacodynamics
• Pharmacokinetics
• Safety Pharmacology

Disease Models Screening (show more)

We will create specific disease models to accelerate your targeted drug discovery project, including but not limited to
• Models—Knockout models.
CD BioSciences will establish the specific disease models according to your requirements to evaluate the inhibitory activity of your candidates targeted GPR12. We have various cell lines and the species of our animal models cover rats, mice, rabbits, dogs, and non-human primates.

Inquire Us

References

1. Stelzer G.; et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analysis , Current Protocols in Bioinformatics(2016), 54:1.30.1 - 1.30.33.doi: 10.1002 / cpbi.5.
2. Wishart DS; et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue): D901-6.
3. Y. Zhou; et al. Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. Nucleic Acids Research. 50(D1): 1398-1407 (2022). PMID: 34718932.